‹ ›
MYP_062920
← PREVIOUS NEXT → BACK
Basic Information
Eval418
Anticancer ▸ Cytotoxic anticancer activity ▸ Cytotoxic
Antimicrobial
Antiviral
Antiviral ▸ Anti-Herpesvirus ▸ Anti-HSV
Antiviral ▸ Antiviral mechanism ▸ Viral entry inhibition
Toxicity / Safety ▸ Blood cell toxicity ▸ Hemolysis ▸ Hemolytic
Toxicity / Safety ▸ Cytotoxicity ▸ Cytotoxic
Venom / Toxin ▸ General toxin ▸ Cytotoxic
Standard
13 amino acids
C74H113N17O18
Standard
Sequence
LWGEIWNTVKGLI
Physicochemical Analysis
1528.79 Da
6.00
-0.24
-0.44
-0.0183
0.51
0.47
0.42
22.70
142.31
0.1538
11000.00
11000.00
The radar chart summarizes major physicochemical dimensions for quick comparison, while exact numerical values remain listed on the left.
Residue Composition
Amino Acid Composition
Chemical Descriptors
570.74
-0.98
20.0
18.0
48.0
109.0
4.0
13.0
Structural Visualization
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber in the current view mode. Use the buttons to zoom.
2D CHEMICAL STRUCTURE
Drag to move
Drag to move. Use the buttons to zoom.
Experimental Records
RECORD: Rec_0307822 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
Synthetic peptide
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
Amidation
Bio-Activity Profile
Antiviral Anti-HSV
Herpes simplex virus type 1 (HSV-1) | Vero cells
2.48 μg/mL
IC50
Mammalian: 5.5 h; Yeast: 3 min; E. coli: 2 min
PaperHistidine-rich Modification of a Scorpion-derived Peptide Improves Bioavailability and Inhibitory Activity against HSV-1. | Zeng Z, Zhang R, Hong W, Cheng Y, Wang H, Lang Y, Ji Z, Wu Y, Li W, Xie Y, Cao Z. | Theranostics. 2018 Jan 1;8(1):199-211. | DOI:10.7150/thno.21425 | PMID:29290802 PMID29290802 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/29290802/
RECORD: Rec_0321469 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
Amidation
Bio-Activity Profile
Antimicrobial Antiviral
HSV-1:inhibition of viral inactivation in Vero cells
2.48 μg/mL
IC50
PaperPubMed PMID: 29290802 PMID29290802 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/29290802/
RECORD: Rec_0333361 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
Synthetic peptide
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
Amidation
Bio-Activity Profile
Antiviral
inhibition of viral attachment in Vero cells
3.7 μg/mL
IC50
Mammalian: 5.5 h; Yeast: 3 min; E. coli: 2 min
PaperHistidine-rich Modification of a Scorpion-derived Peptide Improves Bioavailability and Inhibitory Activity against HSV-1. | Zeng Z, Zhang R, Hong W, Cheng Y, Wang H, Lang Y, Ji Z, Wu Y, Li W, Xie Y, Cao Z. | Theranostics. 2018 Jan 1;8(1):199-211. | DOI:10.7150/thno.21425 | PMID:29290802 PMID29290802 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/29290802/
RECORD: Rec_0337309 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
Synthetic peptide
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
Amidation
Bio-Activity Profile
Antiviral Anti-HSV Entry inhibition
HSV-1 | Vero cells
1.622 μM
IC50
Mammalian: 5.5 h; Yeast: 3 min; E. coli: 2 min
PaperHistidine-rich Modification of a Scorpion-derived Peptide Improves Bioavailability and Inhibitory Activity against HSV-1. | Zeng Z, Zhang R, Hong W, Cheng Y, Wang H, Lang Y, Ji Z, Wu Y, Li W, Xie Y, Cao Z. | Theranostics. 2018 Jan 1;8(1):199-211. | DOI:10.7150/thno.21425 | PMID:29290802 PMID29290802 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/29290802/
RECORD: Rec_0362134 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
Amidation
Bio-Activity Profile
Antimicrobial Antiviral
PaperPubMed PMID: 29290802 PMID29290802 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/29290802/
FIRST PREV 1 2 3 4 NEXT LAST
Showing 5 records on this page · Page 3 of 4